FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to production of modified exotoxins Pseudomonas, and can be used in medicine for anticancer therapy. Exotoxin A Pseudomonas (PE) is obtained, in which the amino acid residue R456 is substituted with alanine, one or combined with F443, substituted with alanine, L477, substituted with histidine, R494, substituted with alanine, and/or L552, substituted with glutamic acid or asparagine. Modified PE is used to produce chimeric molecules containing an agent fused with PE or conjugated with PE, which targets a target target cell.
EFFECT: invention enables to obtain exotoxin A Pseudomonas with reduced immunogenicity while maintaining cytotoxicity.
42 cl, 27 dwg, 28 ex, 31 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| EXOTOXIN A PSEUDOMONAS WITH LESS IMMUNOGENIC T-AND/OR B-CELL EPITHOPES | 2012 |
|
RU2627216C2 |
| RECOMBINANT IMMUNOTOXIN AIMED AT MESOTHELIN | 2012 |
|
RU2600067C2 |
| TREATING CANCER BY HUMANISED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR | 2014 |
|
RU2711975C2 |
| gp41-NEUTRALIZING ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2624046C2 |
| M971 CHIMERIC ANTIGEN RECEPTORS | 2013 |
|
RU2658485C2 |
| CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
| ANTI-IGF-1R ANTIBODY AND USE THEREOF AS AN ADDRESS VECTOR FOR CANCER TREATMENT | 2015 |
|
RU2698977C2 |
| BISPECIFIC ANTIBODIES SPECIFIC TO PD1 AND TIM3 | 2016 |
|
RU2729371C1 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| MONOVALENT CARRIER MODULES ACROSS BLOOD-BRAIN BARRIER | 2014 |
|
RU2694659C2 |
